2. Antibody-drug Conjugate/ADC Related JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. Radionuclide-Drug Conjugates (RDCs) EGFR
  4. Cetuximab

Cetuximab  (Synonyms: C225)

Cat. No.: HY-P9905 Purity: 99.70%
COA
SDS
Technical Support

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

For research use only. We do not sell to patients.

CAS No. : 205923-56-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 52 publication(s) in Google Scholar

Other Forms of Cetuximab:

Cetuximab Related Antibodies

Top Publications Citing Use of Products

45 Publications Citing Use of MCE Cetuximab

WB
IHC
Cell Viability Assay

    Cetuximab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 22:e182217.  [Abstract]

    Top: Western blots showing protein expression of MOGAT3 in RKO, RKO EC-R, HT29, and HT29 EC-R cells. Representative blots are shown. MOGAT3KO RKO EC-R and HT29 EC-R, along with RKO EC-R-CTRL and HT29 EC-R-CTRL cell lines, were exposed to 2 μM encorafenib/4 μM cetuximab for 96 hours. Bottom: Relative OD value was assessed to determine cell viability by the CCK-8 assay (n = 3).

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Aug 26;14(14):5443-5460.  [Abstract]

    Cell viability by administrating various concentrations of cetuximab (Cmab) (20-160 μg/mL) and 25 μM HNK in HCT116 and LoVo cells.

    Cetuximab purchased from MedChemExpress. Usage Cited in: J Control Release. 2024 Sep 23:375:643-653.  [Abstract]

    Cell viability of RKO cells after treated by different concentrations of dabrafenib and cetuximab. The concentration gradient of dabrafenib and cetuximab varied from 0.39 to 50 μg/mL.

    Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594.  [Abstract]

    Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by western blot analysis

    Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594.  [Abstract]

    Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by IHC analysis.

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The effect of cetuximab and β-elemene in combination (25 μg/mL) with other cell death inhibitors on the cell viability of KRAS mutant HCT116 and Lovo cells after the treatment for 24 h.

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The expression of positive regulatory proteins for ferroptosis (HO-1 and transferrin) and the negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) were detected by western blotting after the treatment (β-elemene 125 µg/mL, cetuximab 25 µg/mL) for 24 h.

    View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

    View All Isoforms
    RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

    View All EGFR Isoform Specific Products:

    View All Isoforms
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity[1].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    IC50 & Target[1]

    EGFR

    0.147 nM (Kd, Fixed A431 cells)

    RDC Antibody

     

    Soluble EGFR

    0.201 nM (Kd)

    In Vitro

    Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA[1].
    Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cetuximab Related Antibodies
    In Vivo

    Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab significantly reduces the expression of EGFR, pEGFR and Ki67. Cetuximab significantly decreases the expression in the MCT1 and GLUT1 cells but differences are more pronounced in UT-SCC-14 xenografts[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Gene ID

    1956  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.54 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Cetuximab]
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Cetuximab has a significant ADCC effect on A431 cells in a dose-dependent manner.The EC50 for this effect is 43.50 and 39.11 ng/mL.
    Purity & Documentation

    Purity: 99.70%

    SDS (251 KB)

    COA (231 KB)

    Inhibitory Antibodies User Guide (602 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cetuximab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cetuximab205923-56-4C225C 225C-225Radionuclide-Drug Conjugates (RDCs)EGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cetuximab
    Cat. No.:
    HY-P9905
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.